Breast Cancer
Conditions
Keywords
TOP2α, anthracyclines, taxanes, non dose-dense chemotherapy
Brief summary
This is a prospective、multicenter、non-comparative interventional case series. 800 breast cancer patients who have already received chemotherapy prior to this study will be enrolled in the group, including 400 patients received the anthracyclines followed taxanes chemotherapy, and the other 400 patients who have received regiments containing no taxanes. Three tumor tissue slices of all the enrolled patients will be collected for TOP2α assay. Meanwhile, 10 years followed-up survey will be conducted. The relationship of TOP2α expression and 5- year or 10-year disease free survival(DFS) and overall survival（OS）will be identified in this study.
Detailed description
800 breast cancer patients who have received chemotherapy prior to this study will be enrolled in the group, including 400 patients received the anthracyclines followed taxanes chemotherapy(Epirubicin 90 mg/m2 d1, Cyclophosphamide 600mg/m2 d1，21days/cycle, 4 cycles, followed by Docetaxel 75mg/m2,d1, 21days/cycle, 4 cycles;or paclitaxel：Epirubicin 90 mg/m2 d1 cyclophosphamide 600mg/m2 d1, 21day/cycle, 4 cycles, followed by paclitaxel 80mg/m2, weekly, 12 wks), and the other 400 patients who have received regiments containing no taxanes (FEC：5-FU 600mg/m2 d1,Epirubicin 90mg/m2 d1, Cyclophosphamide 500mg/m2 d1, 21day/cycle, 6 cycles; or EC: Epirubicin 90mg/m2 d1, Cyclophosphamide 500mg/m2 d1,21 day/cycle, 6 cycles).The patients will be enrolled in the groups within one month after chemotherapy.Three tumor tissue slices of all the enrolled patients will be collected for TOP2α assay. Meanwhile, 10 years followed-up survey will be conducted. The relationship of TOP2α expression and 5-year or 10-year disease free survival(DFS) and overall survival（OS）will be identified in this study.
Interventions
None listed
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
For inclusion in the study, subjects must fulfil all of the following criteria: 1. . Signed and dated informed consent indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. 2. . Invasive breast cancer confirmed by histology or cytology with the tumor complete resection. 3. . Patients without remote organs metastasis. 4. . The Ages of patients ≥ 18 years and ≤70 years. 5. . Patients with positive axillary lymph nodes, or negative axillary lymph nodes plus one of these conditions: Triple-negative breast cancer, HER- 2(+),Ki-67≥15%. 6. . The values of aspartate aminotransferase(AST),alanine aminotransferase(ALT), alkaline phosphatase(ALP), total bilirubin(TBIL), UREA, CREA were less than 2 times of upper limits of normal at the beginning of aromatase inhibitors（AIs） therapy. 7. . TOP2α is available to be detected in the primary tumour tissue. 8. . Patients received the regimens of anthracyclines followed Taxanes or containing no Taxanes non-dose dense chemotherapy suggested by the guidelines of National Comprehensive Cancer Network （NCCN) 2014.
Exclusion criteria
Any of the following is regarded as a criterion for exclusion from the study: 1. . Patients is in the period of pregnancy or lactation. 2. . Bilateral breast cancer, inflammatory breast cancer or carcinoma in situ. 3. . Previous received neo-adjuvant therapy, including chemotherapy, radiotherapy or endocrinotherapy. 4. . Presence of other life-threatening cancers. 5. . Any severe concomitant condition: uncontrolled cardiac disease or uncontrolled diabetes mellitus. et al.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TOP2αexpressions of participants | one year | The TOP2αexpression levels of the 800 enrolled patients tissue samples will be assayed by immunohistochemistry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Free Survival time of participants | ten year | Ten years followed-up survey will be conducted to identify the 5-year and 10-year Disease Free Survival time of participants. |
| Overall Survival time of participants | ten year | Ten years followed-up survey will be conducted to identify the 5-year and 10-year Overall Survival time of participants. |
Countries
China
Contacts
Primary ContactJin Zhang, Pro.
Outcome results
None listed